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HipTeriparatide is a skeletal anabolic treatment for patients with osteoporosis at high risk for fracture. Because ade-
quate clinical trials have not yet been conducted to assess the efﬁcacy of teriparatide for reducing the risk of hip
fracture, we review here the literature regarding how treatmentwith teriparatide affects the hip in patients with
osteoporosis. Teriparatide increases cancellous bone volume, improves bone architecture, and – uniquely among
osteoporosis treatments – increases cortical thickness and cortical porosity. By bone scan and positron emission
tomography, teriparatide increases bone formation throughout the skeleton, including the hip. Consistent with
these ﬁndings, studies using dual-energy X-ray absorptiometry and quantitative computed tomography for
longitudinal assessment of changes at the hip have consistently shown increases in areal and volumetric bone
mineral density, cortical thickness, and ﬁnite element-estimated hip strength in patients treated with
teriparatide. Finally, in clinical fracture-outcome trials, treatment with teriparatide has been shown to reduce
the risk of nonvertebral fracture, a composite endpoint that includes hip fracture. Taken together, this body of
evidence suggests that teriparatide positively affects the hip in patients with osteoporosis.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Systematic literature review.
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Osteoporosis, a systemic skeletal disease characterized by reduced
bone mineral density (BMD) and disruption in bone microarchitecture,
is the primary cause of non-traumatic hip fractures [1]. The Internation-
al Osteoporosis Foundation estimates that 1.6 million hip fractures
occur annually worldwide; for the year 2050, this ﬁgure is projected
to reach 4.5 to 6.3 million [2].
Hip fractures account for less than 20% of osteoporotic fractures,
however, they represent the majority of fracture-related health care
costs in patients aged 50 years and older [3]. In 2005, the estimated
cost of hip fractures in the United States was 12 billion dollars,
representing 72% of the total annual costs of osteoporotic fractures. By
2025, annual costs for osteoporosis-related fractures are projected to in-
crease by 50% [4]. Hip fractures are furthermore associated with an in-
creased risk of morbidity and mortality [5–7]. Mortality 1 year after
fracture surgery is 27% [6] with the increased mortality for hip fracture
extending to 10 years after the fracture [8]. Between 5% and 10% of pa-
tients experience a recurrent hip fracture; the mean interval between
the ﬁrst and second fractures is 3.3 years [2,8].
Teriparatide was the ﬁrst anabolic agent approved to treat postmen-
opausal women with osteoporosis, men with primary hypogonadal or
idiopathic osteoporosis, and men and women with glucocorticoid-
induced osteoporosis who are at high risk for fracture [9]. Given the
importance of hip fractures, the effect of teriparatide on hip fracture
risk is a clinically important question. However, adequate clinical trials
to test the effect of teriparatide speciﬁcally on hip fractures have not
been conducted. Additionally, the effect of teriparatide to reduce BMD
of the radius has raised questions about the effects of the drug on corti-
cal bone [10]. Accordingly, our goal was to review published informa-
tion regarding the effect of teriparatide at the hip. The focus of this
review is on use of the US Food and Drug Administration-approved
dose of teriparatide (recombinant human PTH [1–34]) 20 μg/day ad-
ministered by subcutaneous injection) in patient populations that are
generally consistent with product labeling.
Methods
We performed a systematic review of the literature in 2 online data-
bases (Fig. 1). Search terms were: femoral neck OR proximal femur OR
total hip AND osteoporosis AND teriparatide for the years 1946 to July
3, 2013. All ﬁelds were searched without limitation. The search was
not restricted to randomized controlled trials, because we were looking
for breadth of data on the effect of teriparatide at the hip in patients
participating in clinical trials and in real-world community settings.
Following the literature search, all citations were incorporated into a
spreadsheet where duplicates were identiﬁed and removed. We then
retrieved full text publications, which were reviewed for relevance
and inclusion by a physician with clinical expertise in the care of pa-
tients with osteoporosis. A total of 52 articles were excluded for reasons
cited in Fig. 1. Additionally, the authors had personal knowledge of stud-
ies that were added to the review (n = 34).
Results
A total of 89 articles in the reference listing were either identiﬁed
during the literature search or added by the authors; data from some
articles are described in more than one section of this review, when
appropriate. The balance of the 103 articles cited (n = 14) provides
background information.
Skeletal effect of teriparatide by histomorphometric analyses
Speciﬁc histomorphometric information regarding the effects of
teriparatide on the human proximal femur is not presently available;
however, ﬁndings from iliac crest biopsies suggest systemic effectsthat may occur throughout the skeleton, including the hip. For example,
in a study of 69 postmenopausal women with osteoporosis treated
with teriparatide 20 μg/day administered by subcutaneous injection or
zoledronic acid 5 mg/year by IV infusion, the correlation coefﬁcient
was 0.85 (p b 0.0001) between serum concentrations of procollagen
type 1 N-terminal propeptide (a marker of bone formation) at month
6 and mineralizing surface/bone surface (a measure of bone formation)
at month 12, which conﬁrms that these parameters provide similar
information regarding global skeletal bone formation [11]. Effects
of teriparatide demonstrated at the iliac crest may also occur at the
hip, although the magnitude of the change at the hip may differ.
Biopsy specimens collected at the iliac crest from a subgroup of
women (n = 102) who participated in the Fracture Prevention Trial
[12], the pivotal phase-3 fracture trial for teriparatide, provide quantita-
tive structural data about patients treated with teriparatide. Improved
cancellous and cortical bone structure is illustrated in micro-computed
tomography images of paired iliac crest biopsies from three representa-
tive patients (Fig. 2). Histological studies have consistently shown that
teriparatide increases both bone formation and resorption [11,13–18],
and mineralization studies have conﬁrmed the presence of new bone
formation during teriparatide treatment [19,20].
The question arises whether the increased resorption during
teriparatide treatment could have an adverse consequence. However,
evidence to date consistently suggests that the anabolic effect of
teriparatide is manifested both by an increase in bone formation at pre-
viously quiescent surfaces, an effect termed “modeling”, and by
overﬁlling of remodeling sites, both of which lead to increased bone
mass. An analysis of iliac crest biopsy specimens from 55 women who
participated in the Fracture Prevention Trial found that remodeling
sites in patients treated with teriparatide were overﬁlled with new
bone, resulting in an increase in cancellous hemiosteon mean wall
thickness [18,21]. A consequence of this overﬁlling is that, during
teriparatide treatment, bone turnover should induce a progressive in-
crease in bone mass. These mechanisms – overﬁlling and modeling –
may contribute to improvement in cancellous and cortical architecture
Fig. 2. Previously unpublished micro-computed tomography images of paired iliac crest bone biopsies in postmenopausal women with osteoporosis who participated in the Fracture
Prevention Trial. Baseline (pre-treatment) is shown on the left; post-treatment with teriparatide is shown on the right. Patient A) aged 59 and treated for 21 months, Patient B) aged
63 years and treated for 18 months, and Patient C) aged 62 and treated for 22 months. Treatment with teriparatide resulted in increases in cortical thickness, cancellous bone volume,
and connectivity, aswell as the conversion of rods to plates [12]. These patients had increases in BMD frombaseline representative of the overall group of patients treatedwith teriparatide;
increases at the femoral neck BMD were 3.2% for Patient A, 3.2% for Patient B, and a 1.4% for Patient C. Images used with permission of Yebin Jiang.
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with a slightly different dose of teriparatide have also been shown [22]
with increases in bone formation noted in the cancellous and
endocortical compartments. The positive increase in activation frequen-
cy with a positive balance at each remodeling site conﬁrms that
teriparatide meets the deﬁnition of anabolic proposed by Riggs and
Parﬁtt [23]. In theory, the replacement of older bone with new bone
during teriparatide treatment may remove microdamage [24], which
would represent another beneﬁt of increased remodeling induced by
treatment with teriparatide. However, older bone is replaced with
newer undermineralized tissue that is temporarily less stiff and less
strong than fully mature lamellar bone. Presumably, these mechanisms
are systemic effects that occur in the proximal femur, although histolo-
gy studies have not yet been performed at this site.
The increase in remodeling during teriparatide treatment also has
unique effects on cortical bone. One such effect is an increase in cortical
remodeling or porosity [12]. On iliac crest biopsies fromhumans treated
with teriparatide, double-labeling of cortical remodeling sites or pores
indicates that bone formation is underway to replace the previously
resorbed bone with new bone; this ﬁnding is associated with anincrease in cortical thickness (Fig. 3). At the iliac crest, teriparatide has
an effect to increase bone formation both on the periosteal and endoste-
al surfaces and to increase cortical thickness as well as porosity [25]. Al-
though histological evidence of these effects at the proximal femur is
not available, other imaging techniques show these effects as reviewed
below.
Effects of teriparatide assessed by radionucleotide bone scans and positron
emission tomography scans
The effects of teriparatide to increase bone formation can be visual-
ized and quantiﬁed at the whole skeleton level and at regions of inter-
est, such as the hip, using radionucleotide bone scans and positron
emission tomography scans. The effect of daily teriparatide treatment
in 10 postmenopausal women with osteoporosis was assessed using
radionucleotide bone scans at speciﬁc sites of clinical interest including
the hip and spine [26]. The median increases from baseline in whole-
skeleton uptake of technetium-99m methylene diphosphonate were
22.3% (p = 0.004) and 33.7% (p = 0.002) at 3 and 18 months, respec-
tively. The median increases from baseline in lower extremity uptake
Fig. 3. Paired iliac crest biopsy images from 2 postmenopausal womenwith osteoporosis treated with teriparatide showing pre-treatment and post-treatment ﬁndings. These biopsy im-
ages are from the studypublished byMa et al. [25]. Theﬁrst pair of biopsies is from apatient previously treatedwith alendronate and switched to teriparatide. The second pair of biopsies is
from an osteoporosis drug naïve patient subsequently treatedwith teriparatide. Overall bone formation increased as indicated by the increase in tetracycline labeling. An increase in intra-
cortical remodeling (cortical porosity) is shown with double labeling indicative of remodeling of older to newer bone. This increase in cortical porosity is accompanied by periosteal and
endosteal labeling and an increase in cortical thickness. The biopsy images in panel A are reprinted from Bone, Effects of Teriparatide on Cortical Histomorphometric Variables in Postmen-
opausalWomenWith orWithout Prior Alendronate Treatment,MaYanfei L., ZengQingQ., ChiangAlanY., BurrDavid, Li Jiliang, DobnigHarald, Fahrleitner-PammerAstrid,Michalská Dana,
Marin Fernando, Pavo Imre, Stepan Jan J., 2013, doi: 10.1016/j.bone.2013.11.011, with permission from Elsevier. The biopsy images in panel B are previously unpublished.
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these results were statistically signiﬁcant. Thus, by bone scan, the effect
of teriparatide on the lower extremities appears to be similar to the
overall effect on the remainder of the skeleton.
Positron emission tomography was used in 18 postmenopausal
women with osteoporosis treated with teriparatide for 6 months to as-
sess 18F-ﬂuoride standardized uptake values at various skeletal sites
[27]. This technique allows for the regional assessment of bone formation
at clinically relevant sites, including the hip. After 6 months of treatment
with teriparatide, standardized uptake values increased by 37% at the
femoral shaft (p = 0.0019) and 20% at the total hip (p = 0.032). These
data show increased bone formation at the hip during teriparatide treat-
ment, but these imaging techniques do not provide information about
bone resorption or bone balance. From the review of the totality of the
data, the authors concluded that “the changes in bone formation rate
during teriparatide treatment as measured by 18F PET differ at different
skeletal sites, with larger increases in cortical bone than at trabecular
[cancellous] sites”. TMK is a consultant for Amgen Inc., Merck & Co. Inc.,
Agnovos Healthcare LLC, and O.N. Diagnostics LLC; and is a shareholder
of O.N. Diagnostics LLC.
This technique was also used to assess treatment-naive postmeno-
pausal womenwith osteopenia randomized to receive teriparatide, calci-
um and vitamin D (n= 13) for 12 weeks or calcium and vitamin D only
(n = 14) [28]. After 12 weeks of teriparatide, increases in plasma clear-
ance of 18F-ﬂuoride to bone, ameasure of bone formation, were observed
at all regions of interest, including the total hip (+27%, p = 0.002),
femoral neck (+25%, p = 0.040), hip cancellous regions of interest
(+21%, p = 0.017), and the hip cortical regions of interest (+51%,
p = 0.001). In the calcium and vitamin D group, no signiﬁcant changes
in plasma clearance of 18F-ﬂuoride to bone were observed.Effect of teriparatide on BMD using dual-energy X-ray absorptiometry
(DXA)
The effect of teriparatide to increase bone formation, as demonstrat-
ed by studies of iliac crest biopsies, bone scans, and positron emission
tomography, would be anticipated to increase bone mass and hence
BMD. Areal BMD assessed by DXA at the spine and proximal femur is
a standard means of identifying patients with osteoporosis, and
response to therapy is often assessed by serial BMD testing [1,29]. This
review will focus on the femoral neck and the total hip, the regions of
interest considered to be the most clinically relevant [30,31].
Fracture Prevention Trial and Forteo Alendronate Comparator Trial (FACT)
Bone mineral density was evaluated as a secondary endpoint in the
phase-3 randomized, double-blind Fracture Prevention Trial of 1637
postmenopausal women with osteoporosis [10]. Compared with place-
bo, teriparatide 20 μg/day increased femoral neck and total hip BMD by
3.5% (p b 0.001) and 3.6% (p b 0.001), respectively, after a median of
19 months of treatment and 21 months of observation. Treatment
with teriparatide produced statistically signiﬁcant increases in BMD at
the hip compared to placebo. Additionally, subgroup analyses using
data from the Fracture Prevention Trial showed that mild or moderate
renal impairment [32] and 25-hydroxyvitamin D insufﬁciency [33] did
not appear to affect increases in hip BMD in response to teriparatide.
Hip DXA scans from the Fracture Prevention Trial were analyzed in a
subset of patients using hip structural analysis [34].
In the double-blind FACT, areal BMD at the hip was assessed in 203
postmenopausal women with osteoporosis treated with teriparatide
or alendronate. Teriparatide was associated with an increase of 3.9%
from baseline in areal BMD at the femoral neck after 18 months [15].
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discussed below.
Studies of patients treated with antiresorptive therapies prior to teriparatide
The European Forsteo Study (EUROFORS) was a multinational, pro-
spective, randomized, open-label study (n=865) that evaluated the ef-
fects of teriparatide in subgroups of patients (1) naïve to osteoporosis
treatment, (2) previously treated with osteoporosis therapies, and
(3) with inadequate response to previous osteoporosis treatment [35].
In patients who were treatment-naïve prior to enrollment, total hip
and femoral neck BMD progressively increased from baseline by 1.8
and 2.1%, respectively, after 12 months. However, in patients who had
received prior antiresorptive therapy, losses in total hip and femoral
neck BMD (largest −1.4% in the inadequate responders group,
p b 0.001) were noted at 6 months that were reversed by month 12.
BMD subsequently increased over time; for example, femoral neck
BMD increased from baseline in the inadequate responders group by
2.1% at 18 months and by 3.9% at 24 months [36].
In another study of patients switched from alendronate to
teriparatide, total hip BMDalso decreased at 6 months (by 1.8%), similar
to the ﬁndings in EUROFORS. With continued teriparatide treatment,
total hip BMD increased by approximately 1.5% between months 6
and 18 [37]. A similar study showed that treatment with teriparatide
was associated with a decrease in femoral neck BMD at month 6
(−1.8% vs. baseline), followed by a 2.6% increase after 12 months of
treatment (p b 0.05 vs. baseline) [38]. These data indicate that patients
treated with antiresorptive therapy and switched to teriparatide may
experience a modest decrease in hip BMD followed by a later increase
in hip BMD; for these patients, a full 2-year course of treatment with
teriparatide may be important to maximally increase hip BMD.
In another study, patients previously treated with long-term
alendronate were randomized to either switch to teriparatide
(“Switch” group) or to add teriparatide to ongoing therapy with
alendronate (“Add” group) [39]. In the alendronate Switch group, a
small decline in total hip BMD from baseline was observed at
6 months (−0.8%; p = 0.14) with a small increase above baseline at
18 months (0.9%; p= 0.24). This biphasic response of an early decrease
followed by subsequent increase was not observed in the alendronate
Add group; in that group, total hip BMD increased by 3.2% (p b 0.001)
between baseline and 18 months. In the Add vs. Switch group,
18-month BMD increments were higher at the total hip (3.2 vs. 0.9%;
p = 0.02), but there was no signiﬁcant difference at the femoral neck
(2.7 vs. 2.3%; p = 0.75). These data suggest, in general, that patients
previously treated with alendronate achieve larger increases in BMD
when adding teriparatide to ongoing alendronate rather than switching
to alendronate.
The histological mechanisms described above help explain the early
decreases in BMD at the hip in patients previously treated with
alendronate and switched to teriparatide [37]. During treatment with
a potent antiresorptive drug, the remodeling space is reduced, and the
bone becomes more mineralized via secondary mineralization. During
teriparatide treatment, the remodeling space is re-opened, with older,
more mineralized bone being removed and replaced with newer less
mineralized bone. Overall, these studies suggest an early, apparent
decrease in bone density that is temporary as bone mass continues to
increase and the mineralization of new bone progresses.
In patients previously treated with a less potent antiresorptive agent,
raloxifene, and switched to teriparatide, the typical pattern of progressive
increase in BMD at the hip with no early decrease in hip BMD was ob-
served [37,39]. These results suggest that previous treatment with ralox-
ifene does not affect the hip BMD response to teriparatide.
Combination therapy with teriparatide
Combinations of teriparatide with antiresorptive agents have also
been studied. For example, BMD increases were compared in a random-
ized double-blind trial where subjects received teriparatide 20 μg/dayand placebo (n = 68) or a combination of teriparatide 20 μg/day and
raloxifene 60 mg/day (n=69) for 6 months [40]. Combination therapy
produced a signiﬁcant increase in femoral neck BMD (2.23 ± 0.64%)
and total hip BMD (2.31 ± 0.56%) after 6 months. In a separate trial
evaluating a combination regimen of daily teriparatide 20 μg and a sin-
gle infusion of zoledronic acid 5mg versus either agent alone, combina-
tion therapy also produced greater increases in hip BMD than
teriparatide alone. However, the effects of combined therapy at
12 months were not greater than the effect of zoledronic acid alone
[41]. Similarly, combination teriparatide 20 μg daily and risedronate
35 mg weekly for 18 months in 29 men with low BMD [42] showed
that combination therapy provided greater improvement at the total
hip than teriparatide monotherapy.
Combination therapy with teriparatide 20 μg daily and denosumab
60 mg every 6 months produced signiﬁcantly greater increases in
femoral neck and total hip BMD from baseline than teriparatide at
12 months [43] and 24 months [44]. At 24 months, total hip BMD
increased by 6.3% in the combination group and femoral neck BMD
increased by 6.8% in the combination group. These studies suggest
that combining teriparatide with a potent antiresorptive drug may re-
sult in a greater increase in hip BMD than treatment with teriparatide
alone. However, these combination regimens have not been tested in
large trials to assess fracture efﬁcacy and to fully understand safety,
therefore, it is uncertain whether these combination regimens provide
a greater overall beneﬁt-to-risk proﬁle than treatmentwith teriparatide
alone.
In another study of postmenopausal womenwith severe osteoporo-
sis, 125 patients received teriparatide for 9 months [45]. Patients were
then randomized to continue teriparatide alone, to receive teriparatide
plus raloxifene, or to receive teriparatide plus alendronate for 9 addi-
tional months. From month 9 to 18, increases in total hip BMD were
4% for the alendronate combination group, 1.4% for the teriparatide
monotherapy group, and 1.4% for the raloxifene combination group.
The authors reported that the greatest increases in hip BMD were
with 9 months of teriparatide followed by 9 months of teriparatide
plus alendronate.
Most studies of teriparatide have included open-label calcium
and vitamin D supplementation. Heaney et al. [46] compared BMD
outcomes with teriparatide and either tricalcium phosphate or calcium
carbonate. The combination of teriparatide with either calcium salt
resulted in an approximately equivalent increase in hip BMD.
BMD ﬁndings following discontinuation of teriparatide treatment
There are several reports evaluating BMD after teriparatide treat-
ment was discontinued. Bone mineral density was assessed in patients
who completed the Fracture Prevention Trial and participated in a
follow-up study [47]. After discontinuation of study drug, total hip and
femoral neck BMD further increased in teriparatide-treated patients
who received a bisphosphonate, but total hip and femoral neck BMD
decreased in those who received no follow-up treatment. Sequential
therapywith raloxifene after teriparatide also produced further increase
in hip BMD [48,49].
Men treated with teriparatide
Although osteoporosis is less common in men than in women,
approximately 20% to 25% of hip fractures occur in men, and low
BMD is common in older men [2,50]. In a multicenter, randomized,
placebo-controlled trial [51], 437 men with idiopathic or hypogonadal
osteoporosis were treated with teriparatide for a median duration of
11 months. Therapy with teriparatide signiﬁcantly increased BMD at
the femoral neck versus baseline by 1.5% (p = 0.029 vs. placebo); the
change from baseline at total hip was 1.2% (not signiﬁcant vs. placebo).
A total of 355 of the 437 men in this trial (81%) enrolled in a follow-up
study [52]. During 30 months of additional follow-up, hip BMD tended
to further increase inmen treatedwith antiresorptive therapy following
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who were not treated with antiresorptive drugs.
Glucocorticoid-induced osteoporosis
Glucocorticoid-induced osteoporosis is a leading cause of medication-
induced osteoporosis, and the incidence of new fractures after 1 year
of glucocorticoid therapy can be as high as 17% [53]. Saag et al. conducted
a 36-month, randomized controlled trial to compare the effects of
teriparatide 20 μg/day and alendronate in 428 men and women with os-
teoporosis (aged 22–89 years) who were treated with glucocorticoids
(prednisone equivalent, 5 mg daily or more) for 3 or more months [54].
BMD increases from baseline at the total hip were 3.8% and 5.2%, at
months 18 and 36, respectively, in patients treated with teriparatide
[54,55]. These data suggest that teriparatide increases hip BMD inpatients
with glucocorticoid-induced osteoporosis. Subset analyses from this
study showed no difference in the effect of teriparatide based on baseline
glucocorticoid dose [56] or in Hispanic versus non-Hispanic cohorts [57].
In an open-label trial of men who had taken glucocorticoids for
≥3 months and had a spine or hip BMD T-score ≤−1.5 [58], subjects
were randomized to receive teriparatide 20 μg/day (n = 45) or
risedronate 35 mg/week (n = 47). After 18 months of treatment,
total hip and femoral neck BMD increased from baseline by 2.1% and
1.5%, respectively, in the teriparatide group. These data suggest that
teriparatide increases hip BMD in men with glucocorticoid-induced
osteoporosis.
Additional studies of BMD response
Many studies have reported change in hip BMD in response to
teriparatide in speciﬁc patient populations. For example, data from sev-
eral observational clinical practice or pharmacy practice studies showed
improvements in hip BMD consistent with the data already discussed
[59–62]. Investigators have also shown that prior fracture [63] and
prior parathyroidectomy [64] do not have a negative effect on hip
BMD response to teriparatide and that there was no signiﬁcant differ-
ence with morning versus evening dosing [65]. Other factors that
appear not to affect BMD increases achieved with teriparatide treat-
ment include vitamin D receptor Bsml genotype [66] and Asian or
Indian ethnicity [67–71]. Additional studies assessed the BMD effects
of teriparatide versus ronacaleret [72], variability in BMD response to
teriparatide [73], and the relationship between BMD increase and frac-
ture risk reduction during teriparatide [74].
Effect of teriparatide on the hip determined by quantitative computed
tomography (QCT) scans including ﬁnite element analysis
Areal BMD obtained by DXA is 2-dimensional and projectional, and
does not provide true volumetric BMD or measures of changes in the
cortical and cancellous compartments. Computerized tomography
scans, providing 3-dimensional images, can be used for these purposes.
In addition, QCT scans can provide local measures of cortical thickness
and true cross-sectional geometric information. In addition, QCT images
can provide structuralmeasures of biomechanical signiﬁcance and, ulti-
mately, through ﬁnite element analysis, can provide estimates of bone
strength to various loading modes, as further described below.
The ﬁrst study to document the effect of teriparatide on the proximal
femur using QCT scans was the FACT active comparator trial of
alendronate versus teriparatide in postmenopausal womenwith osteopo-
rosis described in the section Fracture Prevention Trial and Forteo
Alendronate Comparator Trial (FACT) [15]. A subset of 56 postmenopausal
womenwith osteoporosis underwent longitudinal QCT scans of the prox-
imal femur. Teriparatide therapy for 18 months was associated with in-
creases in cancellous volumetric BMD of the femoral neck (4.9%, p b 0.01
vs. baseline),while in the cortical bone compartment, volumetric BMDde-
creased by 1.2%. The decrease in peripheral volumetric BMDmight be a re-
sult of an increase in Haversion remodeling (cortical porosity) and/or
endosteal expansion with new bone that is not fully mineralized [75].Finite element analysis is a computational, noninvasive method
to estimate bone strength from QCT scans. Finite element analysis of
QCT scans has been shown to provide robust estimates of whole bone
strength [76,77], as has been consistently validated for assessment
of whole bone strength in various cadaver studies [76–85]. Data from
48 women participating in the FACT study showed that the median in-
crease in strength of the proximal femur to a lateral fall was 5.4%
(p = 0.06). The strength-to-density ratio increased by 4% (p b 0.05),
indicating that the increase in femoral strengthwas greater than the in-
crease in volumetric BMD [75]. Taking the volumetric BMD andﬁnite el-
ement analysis data together, the increases in cancellous BMD during
teriparatide treatment appeared to dominate the biomechanical re-
sponse, so there was an overall increase in femoral strength (p =
0.06) despite the decrease in peripheral volumetric BMD.
In EUROFORS, femoral neck bone distribution, geometry and indices
of bone strength were assessed via QCT using a Mindways software
(Austin, TX, USA) in 52 postmenopausal womenwith severe osteoporo-
sis [86]. After 24 months of treatment with daily teriparatide, femoral
neck volumetric BMD increased signiﬁcantly by 3.0% compared with
baseline. Cortical cross-sectional area (CSA) increased signiﬁcantly by
4.3%, whereas total CSA remained unchanged, suggesting the occur-
rence of new bone on the endosteal but not the periosteal surface.
Thus, this ﬁnding was not due to expansion of femoral neck diameter,
but rather to an increment in endocortical bone. A buckling index im-
proved signiﬁcantly by 4.3% at 24 months, while indices of bending
strength showed a trend toward improvement. As was the case for the
areal BMD data, this study demonstrated that prior antiresorptive treat-
mentmay delay the hip response to teriparatide. Based on the small and
mostly insigniﬁcant changes at 6 months, this did not appear to lead to
a transient phase of reduced structural parameters. Importantly, the os-
teoporosis treatment-naïve group and the two groups previously treat-
ed with antiresorptive drugs showed similar improvements in femoral
bone density, geometry, and indices of strength between 6 and
24 months. The authors concluded that teriparatide treatment for
24 months consistently improved indices of strength at the femoral
neck. The estimated increases in hip strength as assessed by ﬁnite ele-
ment analysis may be clinically signiﬁcant in patients who are near
the fracture threshold.
Poole et al. [87] performed additional analyses of the same femoral
QCT scans from EUROFORS to assess changes in cortical thickness. The
technique infers cortical thickness locally using assumptions regarding
overall tissue mineral density and image-related noise to provide esti-
mate values of cortical thickness below the resolution of the CT scan.
It is not clear if the technique can distinguish between local changes in
cortical porosity and mineralization due to treatment, especially at the
endosteal surface where there may also be local increases in cancellous
bone and where it can be difﬁcult to distinguish between histologically
deﬁned cortical versus cancellous bone using clinical-resolution CT
scans. The analysis showed increased cortical thickness during
teriparatide treatment at sites typically, according to the authors, in-
volved in sustaining habitual mechanical loading (Fig. 4). No regions
of cortical thinning were noted.
In a clinical trial discussed earlier in the BMD section of this review
[39], ﬁnite element analyses of QCT scans were performed to estimate
hip strength in postmenopausal women with osteoporosis previously
treated with raloxifene 60 mg/day or alendronate 70 mg/week for
≥18 months who were either switched to teriparatide (“Switch”) or
teriparatide was added to ongoing antiresorptive treatment (“Add”)
[88]. In those previously treated with raloxifene, hip volumetric BMD
and strength increased from baseline at 18 months in the Add and
Switch groups (strength, month 18: 2.7% Add group, p b 0.01 and 3.4%
Switch group, p b 0.05). In those previously treated with alendronate,
hip volumetric BMD from baseline at 18 months increased in the Add
but not the Switch group (2.2% vs. 0.0% at 18 months, both p ≤ 0.004
group difference). At 18 months, hip strength increased from baseline
in the Add group (2.7%, p b 0.01) but not the Switch group (0%);
Fig. 4. Cortical thicknessmaps showing severe osteoporosis and the increase in thickness following teriparatide treatment. (A) Baseline cortical thicknessmaps with medial, superior and
posterior views of the femur showing thicker bone (blue/green) at sites of loading including A) inferomedial cortex and B) the calcar femorale regions. Also shown is thin, sub-millimeter
cortex (pink/red) at key fracture sites including C) the subcapital superior neck region. Also labeled are the insertion sites of keymuscles of locomotion; D) gluteusmedius, E) psoasmajor
and F) quadratus femoris (on the interotrochanteric crest). (B) Post-treatment percentage change and (C) statistical signiﬁcancemapswhich together indicate regeneration of bone at A),
B), C), D), E), and F).
Reprinted from Poole KES, Treece GM, Ridgway GR, Mayhew PM, Borggrefe J, et al. (2011) Targeted regeneration of bone in the osteoporotic human femur. PLoS ONE 6(1): e16190.
doi:10.1371/journal.pone.0016190.
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(p = 0.076). These data suggest that previous treatment with alendro-
nate may impact the increase in volumetric BMD and hip strength in
patients that were switched to teriparatide. However, based on other
studies, it is possible that continued treatment with teriparatide
through 24 months might increase volumetric BMD and hip strength
in this setting [86]. Additionally, the estimates of strength by ﬁnite ele-
ment analysis do not consider potential bone quality issues, such as the
replacement of older bone with new bone, which might improve when
switching from alendronate to teriparatide [88].
Effect of teriparatide on nonvertebral fractures
The Fracture Prevention Trial [10] was not designed to assess the ef-
fects of teriparatide speciﬁcally on hip fractures. Although sufﬁcientdata to assess the effects of teriparatide on hip fracture are not available,
the hip is a component of the nonvertebral fracture composite endpoint,
and the effects of teriparatide on this composite endpoint may
directionally suggest the possible effect of teriparatide at the hip. The
Fracture Prevention Trial was the pivotal phase 3 fracture trial for
teriparatide. In this randomized, double-blind, placebo-controlled
study, 1637 postmenopausal women with prior fractures received
daily treatmentwith teriparatide 20 μg or 40 μg, or placebo (median du-
ration of treatment = 19 months, median duration of observation =
21 months). All patients received calcium and vitamin D supplementa-
tion. Patients were asked about nonvertebral fractures at each visit, and
reported fractures were conﬁrmed by a review of a radiograph or radi-
ology report. Pathological and traumatic fractures and fractures of the
face, skull, metacarpals, ﬁngers and toes were excluded. Treatment
with teriparatide 20 μg/day reduced the risk of nonvertebral fragility
Fig. 5. Proportion of patients experiencing nonvertebral fragility fractures in (A) the Frac-
ture Prevention Trial [97] and (B) the treatment phase of the DANCE observational study
[92]. (C) The incidence of hip fractures in the DANCE study (previously unpublished data).
N = number of patients in each treatment group at risk × 100; n = number of fractures;
NVFX = nonvertebral fragility fracture; and TPTD20 = teriparatide 20 μg/day. In the
Fracture Prevention Trial, the relative hazard of NVFX decreased by 7.3% for each addition-
al month of teriparatide 20 μg versus placebo (p = 0.009). In the DANCE study, p values
are derived from a one-sample binomial proportion test vs. the ﬁrst period incidence
rate (reference).
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powered to assess the effects of teriparatide at each particular skeletal
site, but the incidence of each type of fracture appeared to be lower in
the teriparatide versus the placebo group. The number of speciﬁc fragil-
ity fractures in the teriparatide 20 μg/day group (N= 541) versus pla-
cebo group (N = 544) included: hip (1 versus 4), wrist (2 versus 7),
ankle (1 versus 3), humerus (2 versus 2), rib (3 versus 5), foot (0 versus
1), pelvis (0 versus 3), and other (6 versus 8). These results indicate a
signiﬁcant effect of teriparatide to reduce the risk of nonvertebral fragil-
ity fractures. Additional analyses from the Fracture Prevention Trial
have shown the effects of teriparatide on various nonvertebral fracture
endpoints including endpoints where traumatic fractures were includ-
ed in the analysis [89].
Subgroup analyses from the Fracture Prevention Trial have shown
that the effect of teriparatide was not signiﬁcantly different in patients
≥75 years versus b75 years old [90], and was independent of pretreat-
ment bone turnover [91] and baseline 25-hydroxyvitaminD insufﬁcien-
cy or sufﬁciency [33]. In a study that followed 1262 women from the
Fracture Prevention Trial for up to 30 months after treatment was
discontinued, there were 38 nonvertebral fragility fractures in the pla-
cebo group (9.2%) and 30 nonvertebral fragility fractures in the
teriparatide 20 μg/day group (6.9%). The hazard ratio was 0.73 (95%
CI, 0.45–1.18; p = 0.204). The authors concluded the results supported
a sustained effect of teriparatide in reducing the risk of nonvertebral fra-
gility fractures up to 30 months after discontinuation of treatment [47].
Observational studies also suggest a beneﬁt of teriparatide to reduce
the risk of nonvertebral fractures. For example, theDirect Assessment of
Nonvertebral Fractures in Community Experience (DANCE) study
evaluated over 4000 men and women receiving teriparatide for
24 months then followed for an additional 24 months posttreatment
[92]. Over 4 years, a total of 168 nonvertebral fractures were reported
in this observational study, including 21 at the hip. Using the same ac-
counting as that used to illustrate the effect of teriparatide over time
in the Fracture Prevention Trial, the incidence of patients experiencing
a new nonvertebral fragility fracture was 1.42%, 0.91%, 0.70%, and
0.81% for the 4 6-month treatment periods [92]. There was a 47% de-
crease in the odds of fracture in the last 6-month treatment period com-
pared with the ﬁrst 6-month period (p b 0.005), and this trend
persisted after teriparatide treatment was discontinued.
Reports of another observational study, the European Forsteo
Observational Study (EFOS) [93–95], showed similar reductions in
nonvertebral fracture incidence during teriparatide treatment, including
in patients who had a history of prior or current bisphosphonate use [96].
The relationship between duration of treatment and nonvertebral
fracture outcomes was also assessed in a post-hoc analysis of data
from the Fracture Prevention Trial [97]. This analysis showed that the
rate of nonvertebral fracture decreased over time in patients treated
with teriparatide and increased over time in patients treatedwith place-
bo (Fig. 5A). As previously described, the incidence of nonvertebral
fractures decreased over time in the DANCE trial (Fig. 5B) [92]. The inci-
dence of hip fractures in the DANCE study showed similar reductions
from the ﬁrst 6-month period (Fig. 5C, previously unpublished data).
Teriparatide review articles
Several teriparatide review articles were identiﬁed in this review of
the literature [98–103]. To our knowledge, this is the ﬁrst review to
focus on the effect of teriparatide 20 μg daily at the hip.
Summary
This review assembles published data related to the effect of
teriparatide at the hip. To brieﬂy summarize, histology of biopsy sam-
ples from the iliac crest in patients treated with teriparatide shows in-
creased bone formation, improved architecture, and an increase in
bone mass with characteristics of new bone. Bone scan and positron
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an increase in bone formation throughout the skeleton as well as at the
hip. Studies have documented an improvement in areal and/or volumet-
ric BMDat the hip during teriparatide treatment inmen, postmenopausal
women with osteoporosis, and men and women with glucocorticoid-
induced osteoporosis. Special analysis techniques have shown an in-
crease in hip cortical thickness and improved estimates of hip strength
to a sideways fall with teriparatide treatment. Studies involving patients
receiving teriparatide have consistently shown a reduction in
nonvertebral fracture, a composite endpoint that includes the hip. A pre-
viously unpublished analysis from the DANCE study suggests a reduced
incidence of hip fractures during teriparatide treatment.
The data for the clinical scenario of a patient on alendronate
switching to teriparatide for 6 months show a transient decrease in
hip BMD without an associated decrease in strength by ﬁnite element
analysis. Subsequently, hip BMD increases above baseline in studies of
24 month duration. This information highlights that a full 2-year course
of teriparatide may be especially important in patients who are
switched from alendronate to teriparatide. An alternative strategy to
switching from alendronate to teriparatide is to add teriparatide to on-
going alendronate; this approach results in a typical increase in hip BMD
and strength. However, an important caveat is that the BMD and ﬁnite
element analysis information do not capture potential differences in
bone material properties between these approaches.
While the data described in this review consistently suggest a bene-
ﬁt of teriparatide at the hip, there are several limitations. Most impor-
tantly, studies designed to assess the effect of teriparatide to reduce
hip fracture incidence are not available and are unlikely to be conduct-
ed. The human bone biopsy information obtained from the iliac crest
may not be representative of the effects of teriparatide at the hip. Fur-
ther, by virtue of increasing bone turnover, teriparatide treatment re-
sults in resorption of older mineralized bone and its over-replacement
with new bone with a low bone mineral content. Accordingly, BMD
ﬁndings may underestimate the effect of teriparatide on bone mass
at the hip, especially in patients previously treated with potent
antiresorptive drugs, since the resorption of more mineralized bone
and formation of new bone of lower mineral content may result in sta-
bility or even reduction of BMD. The various imaging studies reviewed
had a relatively small sample size, resolution limitations, and are unable
to detect bone quality effects that may be signiﬁcant for teriparatide.
Additionally, none of the special imaging studies have been approved
as surrogate endpoints for evaluating treatment effect on hip fracture
risk.
Recognizing a number of limitations, we conclude that available
published evidence suggests that teriparatide is associated with beneﬁ-
cial effects at the hip in patients with osteoporosis, although the effec-
tiveness of teriparatide to prevent hip fracture remains unproven.Acknowledgments
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